RANI (Rani Therapeutics Holdings) ROC %: -247.64% (As of Mar. 2026)

What is Rani Therapeutics Holdings ROC %?

Rani Therapeutics Holdings RANI -3.22% 32 ROC % is -247.64% as of Mar. 2026. GuruFocus rates RANI with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Rani Therapeutics Holdings's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was -247.64%.

As of today (2026-06-26), Rani Therapeutics Holdings's WACC % is 11.43%. Rani Therapeutics Holdings's ROC % is -188.40% (calculated using TTM income statement data). Rani Therapeutics Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Rani Therapeutics Holdings (NAS:RANI) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Rani Therapeutics Holdings's WACC % is 11.43%. Rani Therapeutics Holdings's ROC % is -188.40% (calculated using TTM income statement data). Rani Therapeutics Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Rani Therapeutics Holdings ROC % Related Terms

Rani Therapeutics Holdings ROC % Historical Data

* Premium members only.

The historical data trend for Rani Therapeutics Holdings's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rani Therapeutics Holdings ROC % Chart

Rani Therapeutics Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROC %

Get a 7-Day Free Trial

-756.36

-929.21

-612.45

-271.26

-204.89

Rani Therapeutics Holdings Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROC %	Get a 7-Day Free Trial															-206.19	-186.42	-138.21	-202.82	-247.64

32GF Score

Rani Therapeutics Holdings Inc RANI

ROC % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Rani Therapeutics Holdings ROC % Calculation

Rani Therapeutics Holdings's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

	ROC % (A: Dec. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Dec. 2024 )	+	Invested Capital (A: Dec. 2025 ))	/ count )
=	-38.31 * ( 1 - 0% )	/	( (23.632	+	13.763)	/ 2 )
=	-38.31	/	18.6975
=	-204.89 %

where

	Invested Capital		(A: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	36.634	-	3.149	-	( 27.639	-	max(0, 19.891	-	29.744	+	27.639	))
=	23.632

	Invested Capital		(A: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	58.621	-	4.206	-	( 49.709	-	max(0, 12.669	-	53.321	+	49.709	))
=	13.763

Rani Therapeutics Holdings's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-33.356 * ( 1 - 0% )	/	( (13.763	+	13.176)	/ 2 )
=	-33.356	/	13.4695
=	-247.64 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	58.621	-	4.206	-	( 49.709	-	max(0, 12.669	-	53.321	+	49.709	))
=	13.763

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	51.879	-	5.467	-	( 43.403	-	max(0, 13.855	-	47.091	+	43.403	))
=	13.176

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

Frequently Asked Questions Learn more about ROC % →

What does a ROC % of -247.64% mean?

Rani Therapeutics Holdings (RANI) has a ROC % of -247.64% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Rani Therapeutics Holdings and its competitors.

Is Rani Therapeutics Holdings' ROC % too high?

Rani Therapeutics Holdings' current ROC % is -247.64%. Overall, Rani Therapeutics Holdings has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.

How does Rani Therapeutics Holdings' ROC % compare to CGTX and INO?

Rani Therapeutics Holdings' ROC % of -247.64% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROC % for a Biotechnology company?

A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROC % mean?

A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Rani Therapeutics Holdings and its competitors. Rani Therapeutics Holdings's current ROC % is -247.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Rani Therapeutics Holdings stock overvalued right now?

Rani Therapeutics Holdings (RANI) has a current ROC % of -247.64%. The current ROC % is -247.64%. Rani Therapeutics Holdings' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROC % calculated?

ROC % is calculated from a company's financial statements. For Rani Therapeutics Holdings (RANI), the current ROC % is -247.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rani Therapeutics Holdings Business Description

Industry Healthcare Biotechnology

Comparable Companies CGTX INO ALDX OTLK CBUS PEPG SEER BMEA COYA VANI VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 2051 Ringwood Avenue, San Jose, CA, USA, 95131

Website https://www.ranitherapeutics.com

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

32GF Score

Get the complete analysis for RANI

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.74

Price

View RANI Analysis

See ROC % data for all stocks →